Derma Sciences Announces Issuance of Two New U.S. Patents For DSC127
PRINCETON, N.J.--(BUSINESS WIRE)--Jul 23, 2012--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the issuance of patents 8,207,233 and 8,207,234 by the U.S. Patent and Trademark Office. These patents provide additional intellectual property protection for the Company’s investigational drug DSC127 by describing the angiotensin peptide in a specific formulation and a method of using the same to treat diabetic foot ulcers.
The inventors are Drs. Kathleen Rodgers and Gere diZerega, both the original inventors of DSC127 and the patent portfolio surrounding the product. The two new patents were issued to the University of Southern California (USC) and have been added to Derma Sciences’ exclusive worldwide licensing agreement with USC. The new patents effectively extend the patent life of the drug through January 2032.
Commenting on the patent awards, Edward J. Quilty, president and chief executive officer of Derma Sciences, said, “DSC127 is an important component of our leadership strategy in advanced wound care and is a key element in our company’s growth plan. We are pleased that our development efforts on this drug for the treatment of diabetic foot ulcers have resulted in additional intellectual property protection in the United States and potentially other parts of the world. These new patents will significantly extend the period of market exclusivity should our planned Phase 3 trials be successful and the drug be approved. We have been working diligently to expand Derma Sciences’ intellectual property position in wound healing and these new patents are important components in ensuring that our work and investments remain ours.” Dr. Rodgers, Associate Professor at the USC School of Pharmacy, added, “I am pleased with the recognition by the patent office of the superior properties of the drug carrier in terms of biocompatibility and optimal drug delivery characteristics.” DSC127 is an analog of a naturally occurring peptide, angiotensin, which has been shown to increase keratinocyte proliferation, increase extracellular matrix production and increase vascularization. Use of this peptide may help the body utilize its own stem cells more productively for wound healing.
About Derma Sciences, Inc. Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, an investigational pharmaceutical drug under development for accelerated wound healing and scar reduction, and is preparing to begin Phase 3 clinical trials. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, BIOGUARD® for infection prevention and TCC-EZ™, a gold-standard off-loading device for diabetic foot ulcers. For more information please visit www.dermasciences.com.
Forward-Looking Statements Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, including clinical trial results, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.CONTACT: Derma Sciences, Inc.
Barry Wolfenson, 609-514-4744 Executive Vice President of Marketing and Business Development email@example.com or LHA Investors Kim Sutton Golodetz, 212-838-3777 firstname.lastname@example.org or Bruce Voss, 310-691-7100 email@example.com @LHA_IR_PR or Media Mackenzie Mills, 212-838-3777 firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES PHARMACEUTICAL SOURCE: Derma Sciences, Inc. Copyright Business Wire 2012 PUB: 07/23/2012 07:30 AM/DISC: 07/23/2012 07:30 AM http://www.businesswire.com/news/home/20120723005354/